References
- Sanz M A, Martín G, Rayón C, Esteve J, González M, Díaz-Mediavilla J, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94: 3015–3021
- De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol 2000; 111: 801–806
- Mi Y, Xue Y, Yu W, Liu S, Zhao Y, Meng Q, et al. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype. Leuk Lymphoma 2008; 49: 524–530
- Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333
- Pantic M, Novak A, Marisavljevic D, Djordjevic V, Elezovic I, Vidovic A, et al. Additional chromosome aberrations in acute promyelocytic leukemia: characteristics and prognostic influence. Med Oncol 2000; 17: 307–313
- Slack J L, Arthur D C, Lawrence D, Mrózek K, Mayer R J, Davey F R, et al. Secondary cytogenetic changes in acute promyelocytic leukemia – prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. Clin Oncol 1997; 15: 1786–1795
- Laubach J, Rao A V. Current and emerging strategies for the management of acute myeloid leukemia in the elderly. Oncologist 2008; 13: 1097–1108
- Rosati R, La Starza R, Veronese A, Aventin A, Schwienbacher C, Vallespi T, et al. NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood 2002; 99: 3857–3860
- Imamura T, Kakazu N, Hibi S, Morimoto A, Fukushima Y, Ijuin I, et al. Rearrangement of the MOZ gene in pediatric therapy-related myelodysplastic syndrome with a novel chromosomal translocation t(2;8)(p23;p11). Genes Chromosomes Cancer 2003; 36: 413–419
- Agerstam H, Lilljebjörn H, Lassen C, Swedin A, Richter J, Vandenberghe P, et al. Fusion gene-mediated truncation of RUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer 2007; 46: 635–643